Inactivation of the Tumour Suppressor, PTEN, in Smooth Muscle Promotes a Pro-inflammatory Phenotype and Enhances Neointima Formation

Overview

Journal Cardiovasc Res

Specialty Cardiology & Vascular Diseases

Date 2010 Jan 7

PMID 20051384

Citations 48

Authors

Seth B Furgeson

Peter A Simpson

Insun Park

Vicki VanPutten

Henrick Horita

Christopher D Kontos

Raphael A Nemenoff

Mary C M Weiser-Evans

Affiliations

Soon will be listed here.

Abstract

Aims: Phosphatase and tensin homolog (PTEN) is implicated as a negative regulator of vascular smooth muscle cell (SMC) proliferation and injury-induced vascular remodelling. We tested if selective depletion of PTEN only in SMC is sufficient to promote SMC phenotypic modulation, cytokine production, and enhanced neointima formation.

Methods And Results: Smooth muscle marker expression and induction of pro-inflammatory cytokines were compared in cultured SMC expressing control or PTEN-specific shRNA. Compared with controls, PTEN-deficient SMC exhibited increased phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) signalling and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) activity, reduced expression of SM markers (SM-alpha-actin and calponin), and increased production of stromal cell-derived factor-1alpha (SDF-1alpha), monocyte chemotactic protein-1 (MCP-1), interleukin-6 (IL-6), and chemokine (C-X-C motif) ligand 1 (KC/CXCL1) under basal conditions. PI3K/Akt or mTOR inhibition reversed repression of SM marker expression, whereas PI3K/Akt or NF-kappaB inhibition blocked cytokine induction mediated by PTEN depletion. Carotid ligation in mice with genetic reduction of PTEN specifically in SMC (SMC-specific PTEN heterozygotes) resulted in enhanced neointima formation, increased SMC hyperplasia, reduced SM-alpha-actin and calponin expression, and increased NF-kappaB and cytokine expression compared with wild-types. Lesion formation in SMC-specific heterozygotes was similar to lesion formation in global PTEN heterozygotes, indicating that inactivation of PTEN exclusively in SMC is sufficient to induce considerable increases in neointima formation.

Conclusion: PTEN activation specifically in SMC is a common upstream regulator of multiple downstream events involved in pathological vascular remodelling, including proliferation, de-differentiation, and production of multiple cytokines.

Citing Articles

Unraveling the causal impact of smoking and its DNA methylation signatures on cardiovascular disease: Mendelian randomization and colocalization analysis.

Cao S, Zeng Y, Pang K, Chen M, Guo R, Wu N Clin Epigenetics. 2025; 17(1):1.

PMID: 39748436 PMC: 11694376. DOI: 10.1186/s13148-024-01808-6.

Tudor-SN exacerbates pathological vascular remodeling by promoting the polyubiquitination of PTEN via NEDD4-1.

Wu Y, Chen Z, Zheng Z, Li X, Shu J, Mao R J Biomed Sci. 2024; 31(1):88.

PMID: 39237902 PMC: 11378411. DOI: 10.1186/s12929-024-01076-9.

PTEN: an emerging target in rheumatoid arthritis?.

Zhou P, Meng X, Nie Z, Wang H, Wang K, Du A Cell Commun Signal. 2024; 22(1):246.

PMID: 38671436 PMC: 11046879. DOI: 10.1186/s12964-024-01618-6.

Advances in the study of exosomes in cardiovascular diseases.

Zhang Z, Zou Y, Song C, Cao K, Cai K, Chen S J Adv Res. 2023; 66:133-153.

PMID: 38123019 PMC: 11674797. DOI: 10.1016/j.jare.2023.12.014.

Transcription factors: key regulatory targets of vascular smooth muscle cell in atherosclerosis.

Jiang Y, Qian H Mol Med. 2023; 29(1):2.

PMID: 36604627 PMC: 9817296. DOI: 10.1186/s10020-022-00586-2.

References

Huang J, Niu X, Pippen A, Annex B, Kontos C . Adenovirus-mediated intraarterial delivery of PTEN inhibits neointimal hyperplasia. Arterioscler Thromb Vasc Biol. 2004; 25(2):354-8. DOI: 10.1161/01.ATV.0000151619.54108.a5. View

Kaplan-Albuquerque N, Garat C, Van Putten V, Nemenoff R . Regulation of SM22 alpha expression by arginine vasopressin and PDGF-BB in vascular smooth muscle cells. Am J Physiol Heart Circ Physiol. 2003; 285(4):H1444-52. DOI: 10.1152/ajpheart.00306.2003. View

Schwartz R, Murphy J, Edwards W, Camrud A, Vliestra R, Holmes D . Restenosis after balloon angioplasty. A practical proliferative model in porcine coronary arteries. Circulation. 1990; 82(6):2190-200. DOI: 10.1161/01.cir.82.6.2190. View

Egashira K, Nakano K, Ohtani K, Funakoshi K, Zhao G, Ihara Y . Local delivery of anti-monocyte chemoattractant protein-1 by gene-eluting stents attenuates in-stent stenosis in rabbits and monkeys. Arterioscler Thromb Vasc Biol. 2007; 27(12):2563-8. DOI: 10.1161/ATVBAHA.107.154609. View

Schober A, Zernecke A . Chemokines in vascular remodeling. Thromb Haemost. 2007; 97(5):730-7. View

Agarwal A, Das K, Lerner N, Sathe S, Cicek M, Casey G . The AKT/I kappa B kinase pathway promotes angiogenic/metastatic gene expression in colorectal cancer by activating nuclear factor-kappa B and beta-catenin. Oncogene. 2004; 24(6):1021-31. DOI: 10.1038/sj.onc.1208296. View

Dwarakanath R, Sahar S, Reddy M, Castanotto D, Rossi J, Natarajan R . Regulation of monocyte chemoattractant protein-1 by the oxidized lipid, 13-hydroperoxyoctadecadienoic acid, in vascular smooth muscle cells via nuclear factor-kappa B (NF-kappa B). J Mol Cell Cardiol. 2004; 36(4):585-95. DOI: 10.1016/j.yjmcc.2004.02.007. View

Charo I, Taubman M . Chemokines in the pathogenesis of vascular disease. Circ Res. 2004; 95(9):858-66. DOI: 10.1161/01.RES.0000146672.10582.17. View

Dahia P . PTEN, a unique tumor suppressor gene. Endocr Relat Cancer. 2000; 7(2):115-29. DOI: 10.1677/erc.0.0070115. View

10.

Mourani P, Garl P, Wenzlau J, Carpenter T, Stenmark K, Weiser-Evans M . Unique, highly proliferative growth phenotype expressed by embryonic and neointimal smooth muscle cells is driven by constitutive Akt, mTOR, and p70S6K signaling and is actively repressed by PTEN. Circulation. 2004; 109(10):1299-306. DOI: 10.1161/01.CIR.0000118462.22970.BE. View

11.

Collins T, Cybulsky M . NF-kappaB: pivotal mediator or innocent bystander in atherogenesis?. J Clin Invest. 2001; 107(3):255-64. PMC: 199202. DOI: 10.1172/JCI10373. View

12.

Taubman M, Rollins B, Poon M, MARMUR J, Green R, Berk B . JE mRNA accumulates rapidly in aortic injury and in platelet-derived growth factor-stimulated vascular smooth muscle cells. Circ Res. 1992; 70(2):314-25. DOI: 10.1161/01.res.70.2.314. View

13.

Kumar A, Lindner V . Remodeling with neointima formation in the mouse carotid artery after cessation of blood flow. Arterioscler Thromb Vasc Biol. 1997; 17(10):2238-44. DOI: 10.1161/01.atv.17.10.2238. View

14.

Maehama T, Dixon J . The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 1998; 273(22):13375-8. DOI: 10.1074/jbc.273.22.13375. View

15.

Yamasaki K, Asai T, Shimizu M, Aoki M, Hashiya N, Sakonjo H . Inhibition of NFkappaB activation using cis-element 'decoy' of NFkappaB binding site reduces neointimal formation in porcine balloon-injured coronary artery model. Gene Ther. 2003; 10(4):356-64. DOI: 10.1038/sj.gt.3301875. View

16.

Suzuki A, Yamaguchi M, Ohteki T, Sasaki T, Kaisho T, Kimura Y . T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity. 2001; 14(5):523-34. DOI: 10.1016/s1074-7613(01)00134-0. View

17.

Ji R, Cheng Y, Yue J, Yang J, Liu X, Chen H . MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation. Circ Res. 2007; 100(11):1579-88. DOI: 10.1161/CIRCRESAHA.106.141986. View

18.

Mitra A, Agrawal D . In stent restenosis: bane of the stent era. J Clin Pathol. 2006; 59(3):232-9. PMC: 1860348. DOI: 10.1136/jcp.2005.025742. View

19.

Owens G, Kumar M, Wamhoff B . Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev. 2004; 84(3):767-801. DOI: 10.1152/physrev.00041.2003. View

20.

Monaco C, Paleolog E . Nuclear factor kappaB: a potential therapeutic target in atherosclerosis and thrombosis. Cardiovasc Res. 2004; 61(4):671-82. DOI: 10.1016/j.cardiores.2003.11.038. View